Mereo BioPharma Group plc (MREO)Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
0.32 USD
-0.01
(-4.179%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:23 a.m. EDT
The investment case for Mereo BioPharma is severely compromised by a catastrophic failure in its core business thesis. The company recently announced failed Phase 3 trials, a development that has triggered a massive legal crisis with class-action lawsuits already underway. Fundamentally, the stock is a value trap: despite trading at a low price relative to book value, the enterprise value remains inflated relative to its negligible revenue, and the balance sheet is bleeding cash with no path to profitability visible. The price action confirms this despair, having erased nearly 60% of its value in the trailing twelve months and failing to recover from a previous spike. With no dividend to provide income and a legal overhang threatening further dilution or delisting, the security offers no margin of safety. The options market reflects this consensus of doom, with traders buying deep out-of-the-money puts while ignoring any potential for recovery. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.111536 |
| MSTL | 0.112257 |
| AutoTheta | 0.181792 |
| AutoARIMA | 0.258958 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.161 |
| Excess Kurtosis | -1.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.003 |
| Market Cap | 51,237,576 |
| Forward P/E | -8.46 |
| Beta | 0.29 |
| Website | https://www.mereobiopharma.com |
As of July 11, 2026, 4:23 a.m. EDT: Speculators are overwhelmingly bearish, positioning exclusively for downside protection with zero call volume across all expirations. Put open interest is concentrated at strikes significantly above the current price ($1.00 to $3.00), indicating a strong expectation of further decline rather than a bounce. Implied volatility is elevated on these protective puts, reflecting fear of continued deterioration.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8052325 |
| Address1 | One Cavendish Place |
| Address2 | 4th Floor |
| All Time High | 8.48 |
| All Time Low | 0.2 |
| Ask | 0.4173 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,489,900 |
| Average Daily Volume3 Month | 3,467,260 |
| Average Volume | 3,467,260 |
| Average Volume10Days | 1,489,900 |
| Beta | 0.294 |
| Bid | 0.2291 |
| Bid Size | 2 |
| Book Value | 0.213 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.321 |
| Current Ratio | 6.481 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.3314 |
| Day Low | 0.316 |
| Display Name | Mereo BioPharma |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,451,400 |
| Earnings Timestamp Start | 1,786,451,400 |
| Ebitda | -35,262,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.426 |
| Enterprise To Revenue | 30.029 |
| Enterprise Value | 15,014,573 |
| Eps Current Year | -0.0282 |
| Eps Forward | -0.03792254 |
| Eps Trailing Twelve Months | -0.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.2966 |
| Fifty Day Average Change | 0.024399996 |
| Fifty Day Average Change Percent | 0.08226566 |
| Fifty Two Week Change Percent | -80.523254 |
| Fifty Two Week High | 2.37 |
| Fifty Two Week High Change | -2.0489998 |
| Fifty Two Week High Change Percent | -0.8645569 |
| Fifty Two Week Low | 0.2 |
| Fifty Two Week Low Change | 0.12100001 |
| Fifty Two Week Low Change Percent | 0.605 |
| Fifty Two Week Range | 0.2 - 2.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,556,112,600,000 |
| Float Shares | 117,160,059 |
| Forward Eps | -0.03792254 |
| Forward P E | -8.464623 |
| Free Cashflow | -14,362,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.734 |
| Gross Profits | 367,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0074699996 |
| Held Percent Institutions | 0.47896 |
| Implied Shares Outstanding | 159,618,609 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom. |
| Long Name | Mereo BioPharma Group plc |
| Market | us_market |
| Market Cap | 51,237,576 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_307970474 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -35,710,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 51,860,084 |
| Number Of Analyst Opinions | 6 |
| Open | 0.33 |
| Operating Cashflow | -26,954,000 |
| Operating Margins | -71.822 |
| Payout Ratio | 0.0 |
| Phone | 44 33 3023 7300 |
| Pre Market Change | 0.0 |
| Pre Market Change Percent | 0.0 |
| Pre Market Price | 0.321 |
| Pre Market Time | 1,784,025,772 |
| Previous Close | 0.335 |
| Price Eps Current Year | -11.382978 |
| Price Hint | 4 |
| Price To Book | 1.5070423 |
| Price To Sales Trailing12 Months | 102.47515 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.168 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.014 |
| Regular Market Change Percent | -4.1791 |
| Regular Market Day High | 0.3314 |
| Regular Market Day Low | 0.316 |
| Regular Market Day Range | 0.316 - 0.3314 |
| Regular Market Open | 0.33 |
| Regular Market Previous Close | 0.335 |
| Regular Market Price | 0.321 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 654,371 |
| Return On Assets | -0.41207 |
| Return On Equity | -0.7587 |
| Revenue Per Share | 0.003 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 159,618,609 |
| Shares Percent Shares Out | 0.0369 |
| Shares Short | 5,883,564 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,160,044 |
| Short Name | Mereo BioPharma Group plc |
| Short Percent Of Float | 0.045300003 |
| Short Ratio | 2.16 |
| Source Interval | 15 |
| Symbol | MREO |
| Target High Price | 2.968894 |
| Target Low Price | 0.4959296 |
| Target Mean Price | 1.7234958 |
| Target Median Price | 1.4744215 |
| Total Cash | 36,223,000 |
| Total Cash Per Share | 0.227 |
| Total Debt | 0 |
| Total Revenue | 500,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.901055 |
| Two Hundred Day Average Change | -0.580055 |
| Two Hundred Day Average Change Percent | -0.64375097 |
| Type Disp | Equity |
| Volume | 654,371 |
| Website | https://www.mereobiopharma.com |
| Zip | W1G 0QF |